The SpectraCure interstitial PDT System with IDOSE® has several unique properties.

  • Individualized treatment - The dose plan is based on the patient’s unique target tissue geometry, as well as individual biological and optical properties.
  • Optimized outcome - Best outcome independent of intra-tumor tissue variations is achieved as the light dose from each laser is monitored together with other treatment-related parameters, such as the oxygen and photo-sensitizer concentration. This also allows for dose adjustments in real time.
  • High precision therapy - 3D image-based treatment planning using advanced dose-planning tools to control light exposure results in precise boundaries between treated and spared/non-treated tissue.

Potential benefits to the patient include:

  • Minimally invasive procedure - Depending on tumor location treatment can be done on an outpatient basis.
  • Repeatable if needed - In contrast to conventional radiotherapy, the treatment is safe to repeat should the cancer recur.
  • No harmful substances - The photosensitizing drug (already approved and available on the market in most countries) is administered only once and clears the body in hours. No ionizing radiation is used.
  • Limited side effects - Thanks to the precise procedure surrounding healthy tissue will be spared, limiting side effects, while the therapy is still effective.

The SpectraCure treatment step-by-step

Treatment - Step 1

00:00 – 00:15
The procedure starts by acquisition of ultrasound images of the prostate for the IDOSE® software.

Treatment - Step 2

00:15 – 00:30
The IDOSE software produces a 3D computer model of the prostate based on the ultrasound images.

Treatment - Step 3

00:30 – 01:00
Thin needles are inserted into the prostate by ultrasound guidance, at positions provided by the IDOSE tratment plan.

Treatment - Step 4

01:00 – 02:00
Delivery of the treatment light starts. The light dose is monitored continuously and adjusted if needed.